TMB-365

TaiMed Biologics Inc. · Phase 2 active Biologic

At a glance

Generic name	TMB-365
Sponsor	TaiMed Biologics Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study (PHASE2)
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals (PHASE1, PHASE2)
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TMB-365 CI brief — competitive landscape report
TMB-365 updates RSS · CI watch RSS
TaiMed Biologics Inc. portfolio CI